4.69
-0.01 (-0.21%)
| Previous Close | 4.70 |
| Open | 4.70 |
| Volume | 744,241 |
| Avg. Volume (3M) | 6,259,562 |
| Market Cap | 387,265,568 |
| Price / Book | 1.81 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Replimune Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | -1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | -0.10 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ASTLEY-SPARKE PHILIP | - | 5.01 | -17,657 | -88,462 |
| HILL EMILY LUISA | - | 5.01 | -7,812 | -39,138 |
| PATEL SUSHIL | - | 5.01 | -37,324 | -186,993 |
| SARCHI CHRISTOPHER | - | 5.01 | -8,626 | -43,216 |
| SCHWENDENMAN ANDREW | - | 5.01 | -7,894 | -39,549 |
| XYNOS KONSTANTINOS | - | 5.01 | -14,023 | -70,255 |
| Aggregate Net Quantity | -93,336 | |||
| Aggregate Net Value ($) | -467,613 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 5.01 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| HILL EMILY LUISA | Officer | 18 May 2026 | Sell (-) | 7,812 | 5.01 | 39,138 |
| PATEL SUSHIL | Officer | 18 May 2026 | Sell (-) | 37,324 | 5.01 | 186,993 |
| ASTLEY-SPARKE PHILIP | Director | 18 May 2026 | Sell (-) | 17,657 | 5.01 | 88,462 |
| SARCHI CHRISTOPHER | Officer | 18 May 2026 | Sell (-) | 8,626 | 5.01 | 43,216 |
| SCHWENDENMAN ANDREW | Officer | 18 May 2026 | Sell (-) | 7,894 | 5.01 | 39,549 |
| XYNOS KONSTANTINOS | Officer | 18 May 2026 | Sell (-) | 14,023 | 5.01 | 70,255 |
| Date | Type | Details |
|---|---|---|
| 29 May 2026 | CNBC | Replimune to resubmit twice-rejected drug for approval after FDA shakeup |
| 05 May 2026 | CNBC | FDA commissioner defends agency's drug approval decisions after wave of backlash |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |